CHRS241220C500
- 0.80
- 0.000.00%
Coherus BioSciences Newsroom
Truist Financial Initiates Coherus BioSciences(CHRS.US) With Buy Rating
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Biosciences (CHRS) Receives a Buy From Barclays
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Cuts Target Price to $4
Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $4
Coherus Stock Rallies 19% on Q3 Earnings, Udenyca Production Update
Coherus BioSciences Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
12 Health Care Stocks Moving In Thursday's Intraday Session
TD Cowen Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Coherus Biosciences: Strong Financial Performance and Strategic Cost Management Drive Buy Rating
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Coherus BioSciences Analyst Ratings
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript Summary
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences Non-GAAP EPS of -$0.01 Beats by $0.10, Revenue of $70.77M Beats by $13.96M
Coherus BioSciences | 10-Q: Q3 2024 Earnings Report
Coherus BioSciences | 8-K: Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q3 Revenue $70.8M
Express News | Coherus BioSciences Q3 Adjusted Net Income USD -1.7 Million Vs. IBES Estimate USD -12.1 Million
Press Release: Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update